Source:http://linkedlifedata.com/resource/pubmed/id/16914906
Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:issue |
2
|
pubmed:dateCreated |
2006-8-17
|
pubmed:abstractText |
Little evidence exists regarding the prognostic impact of the major BCR-ABL gene variants (e13a2 and e14a2) in chronic myeloid leukemia (CML) patients diagnosed and treated in the developing Asian countries. In this study, 139 Thai CML patients were followed for a median period of 3 years (range 18-43 months). Clinical presentations of both BCR-ABL gene variant groups (73% e14a2+ and 27% e13a2+) were similar, although e14a2+ patients tended to be older (42 vs. 37 years) and had higher white blood cell counts than e13a2+ patients. The majority of patients in both groups presented with Sokal stage 2-3 (score >0.8) and were categorized as Hasford's intermediate- to high-risk groups (score >780). All patients received oral chemotherapy and 13% underwent allogeneic stem cell transplantation. None received oral tyrosine kinase inhibitors. In the conventional chemotherapy group, the overall survival (OS) rate was slightly better in e14a2+ than in e13a2+ patients (p = n.s.). The median survival in e14a2+ and e13a2+ patients who did not receive stem cell transplantation was 49 and 33 months, respectively (p = n.s.). The type of blastic crisis in e14a2+ and e13a2+ patients was similar, being predominantly myeloid. In conclusion, CML patients in Thailand, despite being much younger, had a comparable OS with those in the Western countries, with no different OS between e14a2+ and e13a2+ patients. Future studies should focus on the impact of novel oral BCR-ABL tyrosine kinase inhibitors on the outcome of Thai CML patients with different BCR-ABL gene variants.
|
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
IM
|
pubmed:chemical | |
pubmed:status |
MEDLINE
|
pubmed:issn |
0001-5792
|
pubmed:author | |
pubmed:issnType |
Print
|
pubmed:volume |
116
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
114-9
|
pubmed:dateRevised |
2008-11-21
|
pubmed:meshHeading |
pubmed-meshheading:16914906-Adolescent,
pubmed-meshheading:16914906-Adult,
pubmed-meshheading:16914906-Antineoplastic Combined Chemotherapy Protocols,
pubmed-meshheading:16914906-Female,
pubmed-meshheading:16914906-Fusion Proteins, bcr-abl,
pubmed-meshheading:16914906-Genes, abl,
pubmed-meshheading:16914906-Genetic Variation,
pubmed-meshheading:16914906-Humans,
pubmed-meshheading:16914906-Leukemia, Myelogenous, Chronic, BCR-ABL Positive,
pubmed-meshheading:16914906-Male,
pubmed-meshheading:16914906-Middle Aged,
pubmed-meshheading:16914906-Neoplasm Staging,
pubmed-meshheading:16914906-Retrospective Studies,
pubmed-meshheading:16914906-Stem Cell Transplantation,
pubmed-meshheading:16914906-Thailand,
pubmed-meshheading:16914906-Transplantation, Homologous
|
pubmed:year |
2006
|
pubmed:articleTitle |
Natural history of Southeast Asian chronic myeloid leukemia patients with different BCR-ABL gene variants.
|
pubmed:affiliation |
Department of Medicine, Division of Hematology, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand. sciaw@mahidol.ac.th
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't
|